Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

The Big 3 companies acting as intermediaries between drugmakers and insurance providers made billions by needlessly jacking ...

Despite initial slow sales, the firm's CEO cited areas for Leqembi's growth and ambitions for an antisense oligonucleotide ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...

“Even in individuals who had not yet developed kidney disease, we could see that kidney function was linked to brain atrophy.

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the initial cognitive damage caused by dementia, and explains how it works ...

Researchers have discovered a three-drug combination that enhances the generation of CAR-T cells, a type of cancer immunotherapy, and could improve CAR-T cell production for clinical treatments. The ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...